We use first and third-party cookies to offer our services and collect statistical data. If you continue browsing this website you accept their use. More information Accept
PRODUCTS / PRODUCT PORTFOLIO
OTHER THERAPEUTIC AREAS

PRODUCT PORTFOLIO

Lesvi's product portfolio comprises CNS pharmaceuticals and nutraceuticals, unique dosage forms and products in other therapeutic areas such as antiemetic, anti-infective, cardiovascular, pain and respiratory diseases.
123456
Product Indication Dosage form Strength
Ethosuximide Epilepsy, absence seizures Soft capsules 250 mg
Ethosuximide Epilepsy, absence seizures Oral solution 250mg / 5ml
Fampridine Multiple sclerosis XR tablets 10 mg
Fingolimod Multiple sclerosis Capsules 0.5 mg
Fluconazol Antifungal Hard capsules 50, 100, 150 and 200 mg
Fluconazol Antifungal Powder for oral suspension 200 mg/5ml 
Fluoxetine Depression Tablets 10 and 20 mg
Flupentixol decanoate Schizophrenia Injection 10mg/ 0,5 ml;  20mg/ ml; 40mg/ ml; 200mg / 10 ml
Imidapril * Hypertension Tablets 5, 10 and 20 mg
Ketorolac Analgesic Film-coated tablets 10 mg
Lacosamide Epilepsy Oral solution 10 mg/ml syrup
Lamotrigine Lamotrigine XR tablets 25/ 50/ 100/ 200 & 300 mg
Levetiracetam Epilepsy Film-coated tablets 250, 500, 750 and 1000 mg
Levetiracetam Epilepsy Granules for oral solution 250, 500, 750, 1000 and 1500 mg
Levetiracetam Epilepsy Oral solution 100 mg/ml
Levetiracetam Epilepsy XR tablets 1; 1,5; 2 and 3 g XR coated minitablets
Levodopa/benserazide Parkinson Tablets 50 mg + 12.5mg
100 mg + 25 mg
200 mg + 50 mg
Levomepromazine Psychosis Oral solution 40 mg/ml
Levomepromazine Psychosis Solution for injection 25 mg/ml
Levomethadone ** Opioids substitution Oral solution 5mg/ ml (bottle 500ml and 1000ml)
FDF PRODUCT PORTFOLIO

[*] Differentiated product
[**] Opioid

Listed products protected by valid patents are developed solely for purposes related to the development, preparation and submission of information to obtain a Marketing Authorisation. In particular these products are under development for uses related to the activities stated in Art. 10.6 of Directive 2001/83/EC amended by the Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004, i.e. activities carried out to obtain a Marketing Authorisation. None of the products are offered for sale or supplied to countries in which they could be in conflict with valid patents.


© Neuraxpharm / LESVI. All rights reserved.